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Background: Multiple chemical sensitivity (MCS) is a chronic condition of unknown etiology. MCS is characterized
by recurrent nonspecific symptoms from multiple organ systems in response to chemical exposures in
concentrations that are normally tolerated by the majority of the population. The symptoms may have severe
impact on patients’ lives, but an evidence-based treatment for the condition is nonexisting. The pathophysiology is
unclarified, but several indicators point towards abnormal processing of sensory signals in the central nervous
system. Pulsed electromagnetic fields (PEMF) offer a promising new treatment for refractory depression and can be
targeted at the brain, thereby activating biochemical cell processes.
Methods/Design: In a parallel, randomized, double-blind, placebo-controlled trial conducted at the Danish
Research Centre for Chemical Sensitivities, the effects of PEMF in MCS patients will be assessed using the Re5
Independent System. Based on sample size estimation, 40 participants will be randomized to either PEMF therapy
or placebo. The allocation sequence will be generated by computer. All involved parties (that is, participants,
investigators, the research nurse, and the statistician) will be blinded to group allocation. The participants will
receive PEMF therapy or placebo applied transcranially 30 minutes twice a day for 7 days a week over 6
consecutive weeks. Outcomes will be measured at baseline, once weekly during treatment, post treatment, and at
2.5-month and 4.5-month follow-up according to a predefined timetable. The primary outcome will be a
measurement of the impact of MCS on everyday life. The secondary outcomes will be measurements of MCS
symptoms, psychological distress (stress, anxiety or depressive symptoms), capsaicin-induced secondary punctate
hyperalgesia, immunological markers in serum, and quality of life.
Discussion: This trial will assess the effects of PEMF therapy for MCS. Currently, there is no treatment with a
documented effect on MCS, and in terms of healthcare there is very little to offer these patients. There is thus a
great need for well-conducted randomized trials aimed at assessing possible treatment effects. A positive outcome
will pave the way for improved healthcare and understanding of this very disabling and overlooked condition.
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Multiple chemical sensitivity (MCS) is a chronic condi-
tion of unknown etiology [1-3]. MCS symptoms are trig-
gered by exposure to common odors and other airborne
chemicals in low concentrations; for example, perfume,
freshly printed newspapers or magazines, cooking fumes
or new electronic equipment. Symptoms related to the
central nervous system (CNS; for example, headache, ex-
haustion, and concentration difficulties) are commonly
reported, but other organ systems such as the airways,
muscles, and joints are also often involved in symptom
reports [4]. In severe cases, MCS can lead to loss of em-
ployment and social isolation [2,5,6]. Other labels have
been ascribed to the symptoms (for example, chemical
intolerance and idiopathic environmental intolerance)
but MCS is widely used in the scientific literature and
will be used here without reference to any assumptions
about etiology. The etiology and pathophysiology of
MCS remain largely unclarified. However, current find-
ings suggest that both biological and psychological
mechanisms are involved [4,7-10]. Within the biological
spectrum, the theory of an abnormal response in the
CNS termed central sensitization is receiving increasing
scientific attention [7-9,11], partly because this hypoth-
esis is compatible with the polysymptomatic manifesta-
tions from multiple organ systems and with the often
reported association with symptoms of negative affec-
tivity and stress [12-17]. The theory of central sensiti-
zation is further supported by recent findings. During
odor provocations, brain imaging studies have demon-
strated a significantly reduced activity in the cerebral
areas that process olfactory stimuli in MCS patients
compared with healthy controls [18,19]. Suggestions
have been made that the observed reduction in cerebral
activity reflects reduced activity in the inhibitory brain
circuits, thus resulting in an increased response to nor-
mal sensory input [19]; that is, central sensitization. In
controlled experimental pain studies, the presence of
central sensitization in MCS has also been supported by
findings of enlarged areas of capsaicin-induced second-
ary mechanical hyperalgesia [20,21]. Capsaicin (the ac-
tive component in chili peppers) injections in the skin
induce secondary mechanical hyperalgesia, which is an
increased sensitivity to mechanical stimuli in the skin
surrounding the injection site and is considered to be a
CNS response.
The development of MCS has been described in two
or three stages [22]: an initiating chemical exposure in-
duces sensory irritation, and is followed by an elicitation
phase in which symptoms are elicited by chemicals in
nontoxic concentrations. As a possible explanation, it
has been hypothesized that the initial chemical exposure
triggers plastic changes in the CNS, which result in a
changed response to a specific chemosensory input –analogous to the development of a persisting pain
condition following an acute pain incident [8]. A third,
generalization phase has been described in which
symptom-eliciting odors and chemicals begin to involve
other and unrelated chemical exposures [2]. This phase
is also compatible with the localization of MCS in the
CNS. Whether the immune system plays a part is un-
known, but increased levels of immunological markers
have been demonstrated among MCS patients [23].
Very few intervention studies aimed at MCS have been
published [24,25] and, apart from these, there have only
been a few published case reports. Hence, it is not cur-
rently possible to make evidence-based therapeutic rec-
ommendations for MCS [26]. In accordance with the
CNS hypothesis, a transient but yet pronounced effect of
electroconvulsive therapy has been reported in a few
MCS patients [27]. As electroconvulsive therapy involves
general anesthesia and muscle relaxants in advance of
cerebral electrostimulation and also potential transient
amnesia, it is a less attractive theraputic option for MCS.
Transcranial magnetic stimulation and pulsed electro-
magnetic fields (PEMF) are more modern technologies
to achieve electrostimulation of the brain without
employing anesthesia or muscle relaxants. Both tech-
nologies involve the generation of a time-varying mag-
netic field, which consists of magnetic flux lines. A
change in the magnetic field produces an electrical
current in conductive materials (for example, tissue).
PEMF differ from transcranial magnetic stimulation in
mainly two aspects: PEMF are based on weak magnetic
fields and are therefore completely unable to induce
action potentials in excitable cells; and the field change
alternates rapidly between minimum and maximum
[28]. The electrical currents generated by PEMF are thus
weak and lead to activation of the biochemical processes
in the cells, especially the growth-related responses.
In 1977 the first therapeutic use of PEMF took place
and was used to treat pseudoarthrosis and nonunions
[29]. Animal studies since then have shown that PEMF
can be used to enhance peripheral nerve regeneration
[30-33], activate neural tissue [34], promote wound
healing [35], enhance the proliferation of chondrocytes
[36], and promote angiogenesis [37] and vasodilation
[33,38]. Currently, PEMF are still mostly used for the
promotion of bone growth and have been approved by
the US Food and Drug Administration to promote the
healing of certain fractures [39]. However, the scope of
application in humans is expanding, because PEMF have
also been shown to have beneficial effects on osteoarth-
ritis [40,41] as well as antidepressive effects when ap-
plied to refractory depressions [42]. The substantial
individual and societal costs of MCS and the lack of
evidence-based therapeutic options call for well-
conducted randomized trials evaluating the effect of a
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coming study, PEMF will be applied transcranially to
treat MCS in a randomized, double-blind, placebo-
controlled trial.Objectives
The main purpose of the forthcoming study is to investi-
gate whether PEMF application using the Re5 Independ-
ent System (Re5 Aps, Frederiksberg, Denmark) can
reduce the impact of MCS on everyday life, such as the
ability to perform domestic chores, take part in social
activities, attend work, and so forth. The secondary pur-
poses are to investigate whether the intervention can
decrease MCS symptoms, psychological distress (stress,
anxiety or depressive symptoms), capsaicin-induced sec-
ondary punctate hyperalgesia, immunological markers in
serum and increase quality of life.Hypotheses
The primary hypothesis is that PEMF therapy can sig-
nificantly reduce the impact of MCS on everyday life in
the intervention group compared with the control
group. The secondary hypotheses are that PEMF therapy
can significantly decrease: general symptoms (that is,
symptoms that are commonly experienced by MCS pa-
tients); exposure-related symptoms (that is, symptoms that
are elicited by exposure to common odors and chemicals);
stress, anxiety or depressive symptoms if present; and the
area of capsaicin-induced secondary punctate hyperalgesia;
the serum concentration of immunological markers (that
is, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13,
IL-17, IL-21, IL-22, IL-23, TNFα, IFNγ); and can signifi-
cantly improve quality of life.Methods/Design
The study will be conducted as a parallel, randomized,
double-blind, placebo-controlled trial with follow-up
after 2.5 and 4.5 months.Participants
Participants will be recruited among MCS patients who are
registered at the Danish Research Centre for Chemical
Sensitivities and have agreed to be contacted for research
purposes, or MCS patients who have had recent contact
with the Department of Dermato-Allergology, Copenhagen
University Hospital Gentofte, Denmark.
Forty participants will be included in the period from
1 April 2013 to 26 July 2013. In the event that fewer par-
ticipants are included during this period, the inclusion
period will be extended to 1 November 2013, to make it
possible to obtain the full number of participants.Inclusion criteria
All participants must be between 18 and 75 years of age
and meet the extended consensus criteria for MCS [43],
which will be put into practice as follows: symptom dur-
ation of at least 6 months; symptoms in response to at
least two of 11 categories of chemical exposure; at least
one CNS symptom and one symptom from another
organ system; symptoms causing lifestyle or functional
impairments that score ≥35 on the Quick Environmental
Exposure and Sensitivity Inventory (QEESI) Life Impact
Scale; symptoms occurring when exposed, and improv-
ing or resolving when triggering exposures are removed;
and symptoms being triggered by exposure levels that
do not induce symptoms in other individuals exposed to
the same levels. Lastly, all participants must also provide
written informed consent.
Exclusion criteria
Participants will be excluded if they report: previous
PEMF therapy; psychosis or a comparable disorder; epi-
lepsy; cerebral tumors; leukemia or malignancies in the
head or neck region; having a pacemaker or other active
implants; pregnancy or nursing; unreliable contracep-
tion; drug or alcohol abuse; a pending application or
intention to apply for early retirement; initiation of
pharmacological treatment that has not stabilized; or
participation in another research study.
Withdrawal
Participants will be withdrawn from the study treatment
if this is their wish, if they for some reason cannot
complete the required PEMF treatments, or if they ex-
perience adverse effects at an unacceptable level. With-
drawn participants will be asked to fill in the weekly
questionnaires until follow-up has been completed.
Randomization
Participants will be randomly allocated with a 1:1 ratio
and in block sizes of 10 to either the intervention group
or the control group. The manufacturer of the Re5 de-
vice (Re5 Aps) will be responsible for the generation of
the allocation sequence by computer for sequential par-
ticipant numbers. Participants will be numbered sequen-
tially according to their entry into the study. From the
allocation sequence, sequentially numbered smartcards
will be loaded with the allocated treatment. The alloca-
tion sequence will be kept locked up in two copies, one
of which the investigators will have access to if a serious
adverse event occurs.
Blinding
Re5 devices will be identical for both study groups and
will be operated using a smartcard, upon which the type
and duration of treatment is loaded. Two types of
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with active treatments, and smartcards that are loaded
with inactive (placebo) treatments. As the appearances
of the smartcards will be identical, both participants and
investigators will be blinded to treatment allocation. Due
to a limited time frame, the allocation sequence will be
unmasked for the investigators when the last participant
has completed PEMF therapy to be able to conduct the
statistical analyses on the post treatment data. The
unmasking of the sequence for the participants will take
place when all participants have completed the last
follow-up. Since the outcome measures at follow-up are
self-rated by the participants and there will be no com-
munication of any kind between the investigators and
the participants, we do not expect that the premature
unmasking of the allocation sequence for the investiga-
tors will have any influence on the follow-up data. A re-
search nurse will remain fully masked and will ensure
that follow-up data are collected.
Intervention
PEMF will be applied using the Re5 Independent Sys-
tem, which consists of the Re5 Independent (pulse gen-
erator), the Re5 Applicator Head (seven coils), and the
Re5 Smartcard. Participants will receive PEMF therapy
or placebo applied transcranially for 7 days a week over
6 consecutive weeks. The duration of treatment will be
30 minutes twice a day; that is, morning (06:00 to 09:00
hours) and evening (17:00 to 20:00 hours). Participants
will receive instructions from the investigators on how
to operate the Re5 device and the treatment will take
place in the participants’ homes. PEMF therapy is pain-
less and participants will be able to read or do whatever
comes naturally to them while wearing the Re5 device.
Participants who receive pharmacological therapy for
MCS or another condition will continue their treatment
unchanged during the study. All medication use will be
registered.
Control visits/calls
During treatment, control visits will be arranged for all
participants at weeks 1, 2, and 4 after initiation of treat-
ment. At these visits, the smartcards – which contain
electronic information on if and when the participants
have received the scheduled treatments – will be moni-
tored in order to check compliance. The monitoring will
be performed without disclosing the concealed treat-
ment allocation. Furthermore, the control visits will
serve to monitor the outcome measurements (filling in
the questionnaires) and to register adverse effects. At
weeks 3 and 5 an email reminder will be sent in advance
to ensure that questionnaires are completed. At this
point, the participants will also be contacted by tele-
phone to keep compliance up and if necessary oncemore to remind them to fill in the questionnaires. A re-
search nurse, who is also blinded to group allocation,
will be assigned to perform the control visits/calls.Baseline characteristics and outcome measurements
To characterize participants at baseline the following
parameters will be registered: age, gender, smoking,
comorbidities, medications, asthma, and neuroticism as
assessed using the NEO Personality Inventory. Asthma
will be assessed using questions adopted from the Stage 1
questionnaire of the European Community Respiratory
Health Study [44]. Asthma will be defined in accordance
with criteria employed by the European Community
Respiratory Health Study as an affirmative answer to at
least one of the following questions: Have you been woken
by an attack of shortness of breath at any time in the last
12 months? Have you had an attack of asthma in the last
12 months? Are you currently taking any medicine
(including inhalers, aerosols or tablets) for asthma?
Outcomes will be measured at baseline (week 0), once
weekly during treatment (weeks 1 to 5), post treatment
(week 6), and at 2.5-month and 4.5-month follow-ups as
shown in Table 1. The self-administered questionnaires
will be completed using an online questionnaire tool.Primary outcome
Quick environmental exposure and sensitivity inven-
tory The QEESI was developed as a screening question-
naire for MCS to facilitate the recording of patient
anamneses [45]. In this study, three of five original scales
will be used by means of an evaluated Danish translation
[46]: Symptom Severity Scale, Chemical Intolerance
Scale, and Life Impact Scale. Each scale contains 10
items that produce a score ranging from 0 to 100. The
QEESI Life Impact Scale is the primary outcome meas-
ure in this trial.Secondary outcomes
Quick environmental exposure and sensitivity inven-
tory The QEESI Symptom Severity and Chemical In-
tolerance Scales will be used to measure the severity of
general symptoms and of exposure-related symptoms,
respectively.Sheehan disability scale The Sheehan Disability Scale is
widely used in psychiatry, but has also been applied to
many other chronic illnesses. This scale uses visuo-
spatial, numeric and descriptive anchors to measure im-
paired functioning in three domains: work, social life
and family life [47]. The scale generates four disability
scores, one for each domain and a total score by adding
up the three individual domain scores.
Table 1 Timetable for outcome measurements
Treatment Follow-up
Week 0a Week 1 Week 2 Week 3 Week 4 Week 5 Week 6b 2.5 months 4.5 months
QEESI Life Impact X X X X X X X X X
QEESI Symptom severity X X X X X X X X X
QEESI Chemical intolerances X X X X X X X X X
SDS X X X X X X X X X
Individual tasks X X X X X X X X X
Noise sensitivity X X X X
SCL-92 Depressive symptoms X X X X X X X X X
SCL-92 Anxiety symptoms X X X X X X X X X
SCL-92 Somatization X X X X X X X X X
PSS-10 X X X X X X X X X
HAM-D6 X X X X X X X X X
WHOQOL-BREF X X X
Capsaicin-induced secondary hyperalgesia X X
Immunological markers X X
aBaseline measurements.
bPost treatment measurements.
QEESI, Quick Environmental Exposure and Sensitivity Inventory; SDS, Sheehan Disability Scale; SCL-92, Symptom Check List-92; PSS-10, Perceived Stress Scale-10;
HAM-D6, 6-item Hamilton Depression Rating Scale; WHOQOL-BREF, World Health Organization Quality of Life – Brief version.
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Impact Scale used as the primary outcome measure, the
participants will be asked to select three tasks in the
areas of work, social life and family life, which are im-
paired by MCS at baseline. The degree of impairment
associated with each task is scored on a scale from 0 to
10 with visuospatial, numeric, and descriptive anchors
similar to the Sheehan Disability Scale.
Noise sensitivity To measure the participants’ sensitiv-
ity to noise, they will be asked to grade their responses
to 10 different noises (for example, drone of a machine,
stroke of a hammer, rustling of paper) on a 5-point
Likert scale.
Symptom Check List-92 The Symptom Check List-92
subscales for depression, anxiety and somatization will be
included. These subscales comprise 35 items on which re-
sponses are rated on a 5-point Likert scale ranging from
‘not at all’ to ‘very much’. The Symptom Check List-92 has
been validated in a general Danish population and norma-
tive data have been established [48,49].
The 6-Item Hamilton Depression Rating Scale The
6-item Hamilton Depression Rating Scale is a short
self-administered measure of depression. The scale has
been shown to be as sensitive as the more widely used
17-item Hamilton Depression Rating Scale to measure
antidepressive treatment effects [50].Perceived Stress Scale The short version of the Per-
ceived Stress Scale consists of 10 questions and mea-
sures self-perception of stress by grading how different
life situations are perceived. The Perceived Stress Scale-
10 has been shown to be a valid and reliable measure of
perceived stress [51].
World Health Organization Quality of Life The brief
version of the World Health Organization Quality of Life
is a short multidimensional questionnaire, which mea-
sures health-related quality of life. The scale consists of
four domains: physical health, psychological well-being,
social relationships and environment [52].
Capsaicin-induced secondary punctate hyperalgesia
Eight linear vectors will be outlined, arranged radiating
at 45° angles on the volar side of the right forearm half-
way between the cubital fossa and the wrist. Participants
will then receive an intradermal injection of 0.1 ml
capsaicin in a concentration of 3.3 μM (1 μg/ml, 0.01%
solution) at the meeting point of the eight vectors using
a 29-gauge disposable needle producing a circular
blister with a radius of 0.5 cm. A handheld mechanical
probe (diameter 0.6 mm, weight 50.1 g; Centre for
Sensory-Motor Interaction, Aalborg University, Aalborg,
Denmark) with a blunt tip, which exerts the same force
at each application, will be used to determine the area of
secondary punctate hyperalgesia at 10 and 30 minutes
post injection. During the procedure, participants will be
blindfolded and the probe will be applied to the skin for
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starting from a point well outside the injection site and
then sequentially reapplied to the skin moving along a
vector towards the injection site in steps of 0.5 cm. The
participants will be instructed to report when the
pricking sensation changes in intensity or character to
become more intense, painful, burning or otherwise dif-
ferent. When the participant reports a change in sensa-
tion at two successive points, the first point will be
marked. This procedure will be repeated along all eight
vectors (V1 to V8). The eight marks will be connected to
form an area of secondary punctuate hyperalgesia. The
area will be calculated using trigonometry by the rule of
the area of a triangle, adding up and subtracting the area
of the capsaicin blister:
Area ¼ 0:5⋅ sinð45Þ⋅ðV1⋅V2 þ V2⋅V3 þ…þ V7⋅V8
þ V8⋅V1Þ– π⋅0:52
 
An area will be calculated only when there are at least
two neighboring marks. A double assessment at 10 and
30 minutes post injection will be used to derive a mean
area of secondary punctate hyperalgesia. In addition,
capsaicin-induced pain will be measured by means of a
visual analog scale with a low anchor point (no pain)
and a high anchor point (worst pain imaginable). The
visual analog scale measurement will be transformed
into a numerical value using a ruler.
Immunological markers in serum Blood samples will
be collected from all participants twice during the study:
one sample at baseline and one sample post treatment.
Plasma will be separated by centrifuge within 30 mi-
nutes, frozen at −80°C and stored until analyses in
batches. The serum concentration of the following regu-
lating inflammatory cytokines will be assessed: IL-1β, IL-
2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, IL-21,
IL-22, IL-23, TNFα, IFNγ.
Sample size
The sample size calculation for the primary outcome
measure, the QEESI Life Impact Scale, is based on a
two-sample t test. A recent study among Danish MCS
patients found a mean value of 61.5 with a standard de-
viation of 24.3 on the Life Impact Scale [46]. In this
study, the intervention is expected to induce a 40% de-
crease on this scale. We thus expect the mean QEESI
score in the intervention group to decrease to 36.9 and
the mean QEESI score in the control group to remain
unchanged. Since we do not know the standard devi-
ation of the change score we base our sample size calcu-
lation on the assumption that the standard deviation of
the change score is 24.3. Under these assumptions and
with a two-sided significance level set at 0.05, the studywill require 17 participants in each group to be able to
reject the null hypothesis with a power of 0.80. Expected
dropouts are estimated at three participants in each
group, which means that the total number of partici-
pants needed is 40.Statistical analyses
Statistical analyses will be conducted using SPSS (SPSS
Inc, Chicago, IL, USA) and SAS (SAS Institute Inc, NC,
USA). Data will be anonymized and analyzed by a statis-
tician blinded to the participants’ group affiliation; that
is, intervention group or control group. The statistician
will remain fully masked during planning and conduc-
tion of the statistical analyses. Descriptive statistics for
the two groups will be generated. Intention-to-treat ana-
lyses with a two-sided significance level at 0.05 will be
conducted using the mixed-model repeated-measures
method for continuous measures. This model ensures
that data values which are missing at random will not
create bias. Sensitivity analyses will be used to assess the
possible impact of nonrandomly missing values. Preven-
tion of missing values will be attempted by reminding
(email and/or telephone) the participants to fill in the
questionnaires. Since PEMF therapy is a new approach
to treating MCS, per-protocol analyses will be carried
out additionally to evaluate a possible treatment effect, if
Re5 therapy is applied as specified; that is, compliance
≥80%. The final analyses will be adjusted for baseline
levels to improve power. According to the sample size
calculation, the two-sample t test will have sufficient
power to detect a treatment effect, but a mixed model,
which utilizes all available data, is likely to be more
powerful. The criteria of success in the study are signifi-
cantly positive changes in the intervention group com-
pared with the control group regarding the primary and
secondary outcomes.Ethical considerations
The study has obtained approval from the regional
ethics committee (registration number: H-1-2013-006)
and the Danish Health and Medicines Authority (EUDA
MED CIV-ID number 13-01-009621) and is registered
with the Danish Data Protection Agency.
In previous studies, only few and mild adverse effects
related to transcranial PEMF therapy have been repor-
ted. These include mild transient nausea and headache.
If serious adverse events should occur, an evaluation will
be carefully conducted in order to establish whether the
event is related to PEMF therapy or other parts of the
study. If an association between the serious adverse
event and PEMF therapy is suspected, the allocation se-
quence for the participant concerned will be unmasked.
Any adverse effect or event reported during the study
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ities and in future publications.
The study will be conducted in accordance with Good
Clinical Practice guidelines and will be monitored by the
GCP Unit at Copenhagen University Hospital.Discussion
MCS is a condition that may have substantial individual
and social consequences. In spite of this, an effective treat-
ment for MCS has not yet been documented. This trial
will test whether PEMF therapy can effectively ameliorate
the negative effects of MCS in a randomized controlled
design. The main strength of the study is that this is the
first randomized, double-blind, placebo-controlled trial
assessing a possible treatment for MCS. The results will
show whether PEMF therapy is beneficial for MCS pa-
tients in terms of impact on patients’ lives, symptoms,
psychological distress, life quality and whether an associ-
ated capsaicin-related CNS response and immunological
markers are influenced by the intervention.
Some limitations of the study must be considered. Al-
though the case criteria used in this study are generally
accepted, there is no officially approved case definition
for MCS and the case criteria are based on self-report
because no objective clinical tests are available to con-
firm the condition.
Furthermore, the study will include MCS patients who
experience severe functional impairments because of
MCS, which means that the outcomes of the study may
not be applicable to all MCS cases. However, in light of
the absence of objective clinical tests, functional impair-
ment is a clinically relevant parameter in the assessment
of a possible treatment effect. Apart from the fact that a
treatment with well-documented effects on MCS is ab-
sent, there is very little else to offer these patients in
terms of healthcare in general. There is thus a great
need for well-conducted randomized trials aimed at
assessing possible treatment effects. PEMF therapy is a
promising treatment, which can be targeted at the CNS,
and a positive outcome of this trial will pave the way for
improved healthcare and understanding of this very dis-
abling and overlooked condition.Trial status
Participants are being recruited for the study.Abbreviations
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